Aims: Transmyocardial laser revascularization is a treatment for patients with severe angina pectoris not eligible for conventional revascularization. The effects on myocardial function and reversible ischaemia have not been clarified.
Methods And Results: One hundred patients with refractory angina not eligible for conventional revascularization were randomized 1:1 to receive continued optimal medical treatment or transmyocardial revascularization with CO(2)laser in addition to medical treatment. Dobutamine stress echocardiography examinations were performed at baseline and at 3 and 12 months after randomization. The effects of transmyocardial revascularization on myocardial function and reversible ischaemia were assessed by visual interpretation of cineloops at rest and during stress in a 16-segment model. After transmyocardial revascularization resting left ventricular wall motion abnormalities increased (P<0.01), whereas wall motion during dobutamine stimulation remained unchanged. The number of probably non-viable segments increased (P<0.01) with a corresponding decrease in the number of ischaemic segments. Fewer patients had the dobutamine infusion discontinued because of chest pain after transmyocardial revascularization with laser, but the chest pain threshold did not increase significantly.
Conclusion: Following transmyocardial revascularization, resting wall motion abnormalities worsened, wall motion abnormalities during dobutamine stimulation remained unchanged and the number of probably non-viable segments increased.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/euje.2001.0097 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New Directions in Coronary Revascularization for Refractory Angina: Gene Therapy and the Lizard Heart.
Semin Thorac Cardiovasc Surg
December 2024
Department of Surgery, Division of Cardiac Surgery, The Ohio State University, Columbus, Ohio. Electronic address:
Refractory angina is a debilitating disease with limited therapeutic options that is primarily caused by microvascular dysfunction and desertification. Towards addressing this unmet need, microvascular revascularization therapy has progressively evolved from the lizard heart inspired transmyocardial revascularization to precisely inducing vascular endothelial growth factor with gene therapy. Gene therapy with adenoviral vehicles or naked modified ribonucleic acid is safe and shows early signs of clinical promise but has not yet been proven effective due to gaps in optimization.
View Article and Find Full Text PDFSynergistic Effect of Transmyocardial Revascularization and Platelet-Rich Plasma on Improving Cardiac Function After Coronary Artery Bypass Grafting.
Cureus
May 2024
Department of Research, NFSci, LLC, Tucson, USA.
Background Coronary artery disease (CAD) is a global health burden, contributing to mortality and morbidity. A proportion of patients with CAD suffer from diffuse CAD, where conventional revascularization techniques such as percutaneous coronary intervention and coronary artery bypass grafting (CABG) may be insufficient to adequately restore myocardial perfusion. Transmyocardial revascularization (TMR) uses a laser to create microscopic channels in the myocardium, inducing inflammation, angiogenesis, and neovascularization to improve perfusion to ischemic regions.
View Article and Find Full Text PDFNovel Concepts in the Management of Angina in Coronary Artery Disease.
Curr Pharm Des
September 2023
1st Cardiology Department, "Hippokration" General Hospital, University of Athens Medical School, Athens, Greece.
Article Synopsis
- Coronary artery disease is common and severely impacts the quality of life, particularly through stable angina pectoris, which can be hard to manage despite treatment efforts.
- Enhanced external counterpulsation and coronary sinus reduction are among the promising techniques developed to improve blood flow and alleviate chronic angina, though clinical trials are limited in size.
- Other approaches, such as transmyocardial laser revascularization and spinal cord stimulation, have shown disappointing results and are not recommended, while angiogenic therapies show potential but require more substantial research for validation.
Autologous CD133 + Cells and Laser Revascularization in patients with severe Ischemic Cardiomyopathy.
Stem Cell Rev Rep
April 2023
Department of Cardiothoracic Surgery, University of Kentucky, Lexington, KY, USA.
Objective: We tested the hypothesis that targeted TMLR combined with intramyocardial injection of autologous CD 133 progenitor cells is safe and feasible in patients with chronic ischemic cardiomyopathy (ICM) and no revascularization options.
Methods: Eight male patients (age 62 ± 2.4 years) with multivessel severe ischemic heart disease and no revascularization options were enrolled.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!